Estimating the Lost Benefits of Antiretroviral Drug Use in South Africa
- 1 December 2008
- journal article
- perspectives
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 49 (4) , 410-415
- https://doi.org/10.1097/qai.0b013e31818a6cd5
Abstract
South Africa is one of the countries most severely affected by HIV/AIDS. At the peak of the epidemic, the government, going against consensus scientific opinion, argued that HIV was not the cause of AIDS and that antiretroviral (ARV) drugs were not useful for patients and declined to accept freely donated nevirapine and grants from the Global Fund. Using modeling, we compared the number of persons who received ARVs for treatment and prevention of mother-to-child HIV transmission between 2000 and 2005 with an alternative of what was reasonably feasible in the country during that period. More than 330,000 lives or approximately 2.2 million person-years were lost because a feasible and timely ARV treatment program was not implemented in South Africa. Thirty-five thousand babies were born with HIV, resulting in 1.6 million person-years lost by not implementing a mother-to-child transmission prophylaxis program using nevirapine. The total lost benefits of ARVs are at least 3.8 million person-years for the period 2000-2005.Keywords
This publication has 19 references indexed in Scilit:
- The Survival Benefits of AIDS Treatment in the United StatesThe Journal of Infectious Diseases, 2006
- ErratumAIDS Care, 2006
- Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countriesThe Lancet, 2006
- AIDS Researchers Decry Mbeki's Views on HIVScience, 2000
- South Africa's AIDS care thrown into confusionThe Lancet, 1999
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987